Legendary investor Bill Miller is the former chairman and chief investment officer of Legg Mason Capital Management. He has been named fund manager of the decade by Morningstar and ranked as the top 30 most influential people in investing by SmartMoney. Below is an edited summary of his interview with The Investor’s Podcast where he talks about determining the intrinsic value of various companies like Amazon, Apple, and Tesla Motors.
Listen to this interview in your car by subscribing to the show on iTunes or Stitcher.
Preston Pysh: How does your approach differ from other famous value investors like Warren Buffett or Joel Greenblatt?
Bill Miller: Every value investor has a unique style, and my difference is that I am more eclectic. Buffett has said that he has moved on from the old Benjamin Graham style of deep values to a style that favors purchasing solid businesses at fair prices that compound on themselves. I am comfortable with both methods. Greenblatt used to prefer a concentrated style with high returns on capital, but now he has hundreds of companies with good financial characteristics in order to lower the volatility. On the contrary, I am skeptical of volatility. Since the financial crisis, volatility has been the price for performance in the risk-averse environment. I am willing to tolerate a lot more perceived risk in the portfolio than most other value investors.
Top 5 Warren Buffett Stocks To Invest In 2019: Oaktree Capital Group, LLC(OAK)
- [By Matthew Frankel, Jordan Wathen, and Dan Caplinger]
With that in mind, here’s why three of our contributors think Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B), Oaktree Capital (NYSE:OAK), and BlackRock (NYSE:BLK) are excellent penny stock alternatives.
- [By Max Byerly]
Oaktree Capital Group LLC (NYSE:OAK) – Analysts at Oppenheimer reduced their Q2 2019 earnings per share estimates for Oaktree Capital Group in a report released on Tuesday, February 5th. Oppenheimer analyst L. Rudary now expects that the asset manager will earn $0.50 per share for the quarter, down from their prior forecast of $0.65. Oppenheimer also issued estimates for Oaktree Capital Group’s Q3 2019 earnings at $0.60 EPS.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Oaktree Capital Group (OAK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Daniel Miller, Jordan Wathen, and Jeremy Bowman]
When it comes to dividend stocks, Coca-Cola Company (NYSE:KO) is a household name. In fact, the beverage giant just approved its 57th consecutive annual dividend increase, bumping it up to $0.40 per share and a juicy yield of 3.5%. But if investors are looking for even bigger dividend yields for their portfolios, three Motley Fool contributors suggest taking a peek at Macy’s (NYSE:M), Oaktree Capital Group (NYSE:OAK), and General Motors (NYSE:GM). Here’s why.
- [By Anders Bylund, Timothy Green, and Brian Feroldi]
Read on to see why our panelists suggest picking up Applied Optoelectronics (NASDAQ:AAOI), Oaktree Capital (NYSE:OAK), and Q2 Holdings (NYSE:QTWO) right now.
Top 5 Warren Buffett Stocks To Invest In 2019: AtriCure Inc.(ATRC)
- [By Shane Hupp]
AtriCure Inc. (NASDAQ:ATRC) shares were up 6.8% on Friday after Needham & Company LLC raised their price target on the stock from $36.00 to $39.00. Needham & Company LLC currently has a buy rating on the stock. AtriCure traded as high as $33.45 and last traded at $33.02. Approximately 2,088,463 shares traded hands during trading, an increase of 931% from the average daily volume of 202,505 shares. The stock had previously closed at $30.93.
- [By Stephan Byrd]
AtriCure (NASDAQ:ATRC) and OxySure Therapeutics (OTCMKTS:OXYS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
- [By Logan Wallace]
Shares of AtriCure Inc. (NASDAQ:ATRC) have received a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $34.25.
- [By Ethan Ryder]
AtriCure (NASDAQ:ATRC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. “
- [By Motley Fool Transcribers]
AtriCure Inc (NASDAQ:ATRC)Q4 2018 Earnings Conference CallFeb. 28, 2019, 4:30 p.m. ET
Prepared Remarks Questions and Answers Call Participants
- [By Dan Caplinger]
The stock market dropped on Friday after major benchmarks once again responded negatively to what many would have thought would be positive news. The latest employment numbers from the Department of Labor’s September report continued to show improving job counts and falling unemployment rates. But some market participants had wanted to see stronger gains in jobs, while others pointed to falling bond prices and rising yields as evidence of fear about the sustainability of current levels of economic growth. Some stocks, however, were able to overcome the dour mood. Chefs’ Warehouse (NASDAQ:CHEF), SMART Global Holdings (NASDAQ:SGH), and AtriCure (NASDAQ:ATRC) were among the best performers on the day. Here’s why they did so well.
Top 5 Warren Buffett Stocks To Invest In 2019: Zynga Inc.(ZNGA)
- [By Lee Jackson]
This is a very aggressive tech play that could have upside above the current price targets. Zynga Inc. (NASDAQ: ZNGA) is a leading developer of mobile and social games. In the company’s relatively short history, it has developed a broad portfolio of games that includes several games on Facebook and several top-grossing mobile apps. Key franchises include FarmVille, Zynga Poker, Hit It Rich Slots and Words With Friends.
- [By Anders Bylund]
Gaming publishers are always looking for the next big thing. The odds of scoring a huge hit are vanishingly small, even for a short-term victory. Consider the case of Zynga (NASDAQ:ZNGA), the social gaming veteran that struck gold with FarmVille and Words With Friends once upon a time. The company went public at the very height of that adrenaline rush. If you bought in at Zynga’s peak share prices in the spring of 2012, you’ve weathered a 70% cut to your investment’s value so far. Like I said, it’s a long way down from the top.
- [By Chris Lange]
Zynga Inc. (NASDAQ: ZNGA) shares made a small gain on Wednesday after Wedbush said that it can see this stock making about a 50% run over the next year and that a turnaround is underway.
- [By Max Byerly]
Zynga (NASDAQ:ZNGA) announced its quarterly earnings results on Wednesday. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02), reports. Zynga had a return on equity of 1.13% and a net margin of 1.70%. The business had revenue of $248.69 million during the quarter, compared to the consensus estimate of $245.78 million. During the same quarter last year, the company earned $0.01 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year.
Top 5 Warren Buffett Stocks To Invest In 2019: Corcept Therapeutics Incorporated(CORT)
- [By Joseph Griffin]
Corcept Therapeutics (NASDAQ:CORT) had its price target reduced by equities researchers at B. Riley from $30.00 to $22.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price objective suggests a potential upside of 76.42% from the stock’s previous close.
- [By Maxx Chatsko]
Shares of Corcept Therapeutics (NASDAQ:CORT) gained over 11% last month, according to data provided by S&P Global Market Intelligence. The double-digit rise might seem impressive, but it comes on the heels of a report by the Southern Investigative Reporting Foundation (SIRF) that painted the company and its main profit generator, Korlym, a drug approved to treat Cushing’s syndrome, in a negative light. That caused the stock to plunge in late January. As a result, shares have posted a year-to-date loss of 6% through the first week of March.
- [By Shane Hupp]
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. acquired 105,792 shares of the firm’s stock in a transaction dated Friday, August 17th. The shares were acquired at an average price of $12.50 per share, with a total value of $1,322,400.00. Following the acquisition, the director now owns 876,838 shares in the company, valued at approximately $10,960,475. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Top 5 Warren Buffett Stocks To Invest In 2019: CBRE Group, Inc.(CBG)
- [By WWW.GURUFOCUS.COM]
For the details of Jeff Ubben’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Jeff+Ubben
These are the top 5 holdings of Jeff UbbenTwenty-First Century Fox Inc (FOX) – 53,326,334 shares, 18.41% of the total portfolio. Alliance Data Systems Corp (ADS) – 5,877,400 shares, 15.07% of the total portfolio. CBRE Group Inc (CBG) – 24,916,923 shares, 10.92% of the total portfolio. Shares reduced by 13.72%KKR & Co LP (KKR) – 47,750,000 shares, 10.18% of the total portfolio. Shares added by 4.82%Morgan Stanley (MS) – 17,959,620 shares,
- [By Ethan Ryder]
Peel Hunt reaffirmed their hold rating on shares of Close Brothers Group (LON:CBG) in a report issued on Tuesday.
Several other equities research analysts also recently issued reports on CBG. Shore Capital reiterated a hold rating on shares of Close Brothers Group in a report on Wednesday, July 18th. Numis Securities upgraded Close Brothers Group to an add rating in a report on Wednesday, July 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of GBX 1,561.30 ($20.34).